ImmuCell Corporation
Material write-down of assets (8-K Item 2.06)
The company reported a material impairment, a large write-down in the recorded value of its assets, in a Form 8-K (Item 2.06) filed on 08 Jan 2026.
More details →Material write-down of assets (8-K Item 2.06)
The company reported a material impairment, a large write-down in the recorded value of its assets, in a Form 8-K (Item 2.06) filed on 29 Dec 2025.
More details →ImmuCell Corporation — Overview & Financial Snapshot
ImmuCell Corporation (NasdaqCM: ICCC) is a Healthcare company, ranked #3,729 of 6,775 companies globally and #1,660 of 4,000 in United States on PositoAI, with a Positivity Score of 20,313. Its market capitalisation is ₹895.00 Cr ($94.82M), P/E ratio is 149.1 and P/B ratio is 3.02. It has no active red flags (PosiRed) and 2 yellow flags (PosiYellow, 6/10 points): Material write-down of assets (8-K Item 2.06); Material write-down of assets (8-K Item 2.06).
For financial statements, ratio trends and score history, Go Deep →